In a word they are a baby amgen. They have a pipeline that is literally unparallel in the immontherapeutic arena. Their two lead candidates Rindo CDX-110 in the treatment of frontline GBM is in phase III, Patients typically expected to live several months at best have survived for several years to date. They have received fast track approval also for CDX-011 that targets mid to high GPNMB in BC, especially TNBC about to enter phase III. They have several other strong pipeline candidates. Their shares are owned 85% institutions. Very thin float. Excellent cash flow. 100% owned pipeline. Secondary 120M done at retail price, RETAIL, back in December. They are on everybody's wish list take over target. However, they pick and choose at will and have turned away potential partners. Although partnership on several aspects of their pipeline (which is more than meets the eye, for example mid to high GPNMB is expressed in numerous cancers; they will probably be partnering on those indications. Also the EGRV111 which is in targeted Rindo (lead candidate) expresses itself elsewhere,mucho. Their Intellectual property is enormous. They are also developing their own diagnostics. They have increase 400% year to date and are still long term 2-3 yrs severely undervalued.
This is a 150+ stock, 3yrs. Much wider/expansive than onxx